-
Prof. Xiaojie Bian at ASCO: Chinese Subgroup Analysis of TALAPRO-2 Shows Survival Benefit with TALA + ENZA in mCRPC
Study Overview In the Chinese subgroup of TALAPRO-2, patients with unselected mCRPC who received talazoparib plus enzalutamide showed improved radiographic progression-free survival (rPFS) based on BICR assessment (HR = 0.30;…
-
Precision Therapy in mCRPC: Prof. Shouzhen Chen Highlights Molecular Subtyping Trends
At ASCO and EAU 2025, Professor Shouzhen Chen (Qilu Hospital, Shandong University) shared an in-depth overview of molecular subtyping in mCRPC. He emphasized established targets like HRR and MSI-H, explored…
-
Facing the Frontlines of Prostate Cancer: Insights from Drs. Zhou Liangping, Wang Qifeng, Yong Jia, and Qi Ma
In a thought-provoking panel discussion, leading Chinese experts Drs. Zhou Liangping, Wang Qifeng, Yong Jia, and Qi Ma tackled several pressing issues in prostate cancer care. The conversation spanned diagnostic…
-
Voices from China at ASCO | Professor Biyun Wang：New First-line Treatment Strategy for mTNBC and Research on the Efficacy Prediction of T-DXd for HER2+ Breast Cancer Brain Metastases Presented
At the 2025 ASCO Annual Meeting, multiple cutting-edge oncology studies were presented. Among them were two studies led by Professor Biyun Wang from Fudan University Shanghai Cancer Center. One was a prospective, single-arm phase II clinical trial (Abstract #1101) evaluating the efficacy and safety of camrelizumab in combination with albumin-bound paclitaxel and cisplatin (the AP…
-
Voices from China at ASCO | Professor Kun Wang Unveils Landmark neoCARHP Study: “Carboplatin-Free” Strategy Redefines Treatment for HER2-Positive Breast Cancer
The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting took place from May 30 to June 3 in Chicago. At this high-profile event, Professor Kun Wang from Guangdong Provincial People’s Hospital presented the much-anticipated results of the neoCARHP study (Abstract LBA500) during an oral session. The study, which focuses on early-stage HER2-positive breast cancer,…
-
Voices from China at ASCO | Prof. Binghe Xu and Prof. Jiayu Wang: Chemotherapy-Free Regimen Combining Anti–PD-L1 and Anti-Angiogenic Therapy Brings New Hope for TNBC Patients
Study Overview Background: Recurrent or metastatic TNBC is a highly aggressive malignancy with poor prognosis. Benmelstobart (TQB2450) is a humanized anti–PD-L1 monoclonal antibody, while anlotinib is an oral multi-targeted tyrosine…
-
Tracing ASCO丨Professor Yongmei Yin: OptiTROP-Breast05 Study Selected for Oral Presentation, Domestic TROP2 ADC Once Again in the Spotlight
Sacituzumab Tirumotecan (sac-TMT) is a novel TROP2-targeted ADC independently developed in China. Over the past two years, its clinical findings have been frequently presented at major international conferences and published in top-tier journals. At the 2025 ASCO Annual Meeting, Professor Yongmei Yin from Jiangsu Provincial People’s Hospital delivered a Rapid Oral Abstract presentation on the…
Connecting Medical Expertise through Media
